Hitching A Ride On The “Failed” Lyft IPO

When it comes to pricing shares for an initial public offering, the author of today’s article notes that they need to be priced “high enough that initial investors can get out at a reasonable profit. And so that the company can raise capital from the stock sales to fund its needs for a while. But they also need to be priced low enough to move higher, to create market confidence. If they fall, it’s considered a ‘failed IPO’.” By this measure, then, it would appear that the recent Lyft IPO was a failed IPO – and that could mean that now is a good time to buy. For more, CLICK HERE.

Read More

Thanks, Obama! (For These 3 Potentially Undervalued Firearms Stocks)

2016-08-01 07_25_45-Morguefile.com free stock photosFirearms makers are going to miss President Obama! As today’s article points out, “eight years of threats by [Obama] of more stringent gun laws have been a financial windfall for firearms companies.” Still, the author states that two publicly-traded gun companies – Sturm, Ruger & Co. and Smith & Wesson Holding Corp. (both of which are up more than 1,000% since Obama’s election in 2008) – are undervalued and worth buying. For more on these stocks – as well as a third stock the author highlights in the realm of electrical weapons and body cameras for law enforcement – CLICK HERE.

Read More

3 Potential “Fallen Angel” Stocks For Bargain Hunters

2016-05-22 21_51_29-Morguefile.com free stock photos“The difficulty with bargain shopping… is that you may be understandably hesitant to buy stocks wallowing near their 52-week lows. In an effort to separate the rebound candidates from the laggards, it makes sense to start by determining whether the market has overreacted to a company’s bad news.” Today’s article highlights three stocks trading near their 52-week lows that the author views as “fallen angels” primed for rebounds. One example? Biopharmaceutical giant Gilead Sciences, which was impacted in Q1 by a drop in sales of its hepatitis C pill but which, the author states, “has an exceptionally deep pipeline of potential blockbusters”, including an HIV treatment recently approved by the FDA. To read more, CLICK HERE.

Read More